Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVID100 in advanced solid tumors
NCT03094169Phase 2Terminated
- Sponsor
- Forbius
- Start
- Feb 2017
- Primary completion
- Nov 2020
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of AVID100 in solid tumor, triple-negative breast cancer (TNBC), head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), sponsored by Forbius. Started Feb 2017; status: terminated.
02
Drugs
AVID100
03
Conditions
solid tumortriple-negative breast cancer (TNBC)head and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03094169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03094169.